Kornimate/medical-research-clean huggingface dataset:
the incidence of postoperative pulmonary complications in patients with a positive and negative air-test during general anesthesia

Conditions: Surgery--Complications; Atelectasis; Anesthesia

Summary: the overall objective of this study is to describe the incidence of postoperative pulmonary complications in patients with a positive and negative air-test result. second, the investigators wish to describe the incidence of a positive air-test and its association with the development of ppc. in addition, the investigators aim to describe whether mechanical ventilation strategy differs between patients with a positive and negative air-test.

the 'air-test', a method wherein inspiratory oxygen concentration is reduced to 21% and pulse-oximetry hemoglobin saturation (spo2) is monitored, can be used to demonstrate the presence of an atelectasis-induced alveolar shunt. it remains uncertain whether an intraoperative positive air-test is associated with clinical outcomes. it is hypothesized that in a general surgical population, the incidence of postoperative pulmonary complications (ppc) is higher in patients with a positive air-test than in patients with a negative air-test. the aim of this study is to describe the incidence of ppc in patients with a positive and in patients with a negative air-test. second, the investigators want to describe the incidence of a positive air-test and its association with the development of ppc. the investigators also want to evaluate whether mechanical ventilation strategy differs between patients with a positive and negative air-test.

Eligibility criteria:
inclusion criteria: * patients undergoing surgery under general anesthesia in the amsterdam university medical centers, location meibergdreef with an endotracheal tube; * patients \> 18 years; * preoperative spo2 of ≥97%; * air-test performed after induction of anesthesia, in a hemodynamic and respiratory steady state. exclusion criteria: * age \< 18 years; * no consent/objection; * patient participated in another conflicting interventional study on mechanical ventilation during general anesthesia

Keywords: anesthesia air-test postoperative pulmonary complications
comparison of phenprocoumon and acetylsalicylic acid (asa)

Conditions: Valvular Calcification; Coronary Calcification

Summary: in this open, prospective, non-randomised, parallel group, unicentric pilot-study will be compared the progress of valvular and coronary calcification with regard to the therapy with either acetyl-salicylic acid or phenprocoumon. the progress of calcification is documented by comparison of cardial stratified computed tomography. it is supposed that treatment with phenprocumon leads to increased coronary and valvular calcification as well to decreased blood levels of carboxylated matrix-gla-protein

patients will be allocated to two groups with either 1. anticoagulation with phenprocoumon (needed for at least 1 year) 2. therapy with asa both treatment groups should include to 50% patients with a glomerular filtration rate (gfr) \ 15 ml/min. all patients will undergo a screening procedure with evaluation of calcium regulating proteins, echocardiography and stratified computed tomography of the heart. medical check up's are planned after 1,3,6, 12 and 18 months. prior investigations concern diastolic ventricular function under long lasting therapy with phenprocoumon and the influence of long lasting therapy with phenprocoumon in patients suffering from aortic valve sclerosis.

Eligibility criteria:
inclusion criteria: * 60 patients with new onset of anticoagulation therapy with phenprocoumon for the expectant duration of at least one year * bmi 19-27 kg/qm * mental ability and capacity to understand and follow the instructions of the investigator * written informed consent exclusion criteria: * patients not fulfilling the inclusion criteria or with: * renal failure grade iv or v * acute cardial or pulmonary decompensation * women of childbearing age, pregnant or breastfeeding women * psychiatric diseases * life expectancy \< 1 year * acute lifethreatening situations * participation in other studies * persons in dependency from the sponsor or working with the sponsor

Keywords: phenprocoumon anticoagulation acetylic salicylic acid need for new anticoagulation treatment
masotherapy with neural tension in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: the objective of this study is to assess if the masotherapy with neural tension is more effective than non-neural tension to improve and reduce tremor in patients with parkinson's disease. the project will be carried out in clinics, where both data collection, assessments and scales will be carried out, as well as the plan and intervention in which the neural tension massage therapy of the radial nerve will be applied to the first intervention group; and massage therapy without neural tension in the second group.

in this study the investigators are going to compare the effectiveness of two treatments (masotherapy with neural tension and masotherapy with non-neural tension) in patients with parkinson disease based on the improved of pain, tremor, functional and life quality. the investigators are going to divide the number of volunteers in two groups. the first group is going to be treated during 8 weeks with conventional (non-neural tension) masotherapy in the upper limb, the other group is going to be treated with radial neural tension masotherapy during 8 weeks also. to apply the neural tension, the investigators position the patient's upper limb lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction. to compare the results between the different groups, the investigators are going to value the patients 4 times, the first one before the beginning of the treatment, the second one and the end of the treatment, the third one after one month completing the treatment, and the last one after three months completing the treatment.

Eligibility criteria:
inclusion criteria: * people diagnosed with parkinson disease in mild or moderate degree. * age between 50-80 years old. * people who can answer the questionnaires without held. * people who commit to attend the treatment assigned in the study. * people with tremor that limit his/her functionality or cause discomfort. * people who is not treated the upper limb exclusion criteria: * people with mental disease. * people who do not sign the informed consent. * people who present comorbidities that can affect the final result of the study. * people whose medication is modified through the study. * people who take medication whose secundary effect is the tremor appearance. * people who is participating in other research studies.

Keywords: parkinson disease essential tremor neuromuscular therapy massage manual therapy neurodynamic
explore the therapeutic effect of theta burst stimulation on emotion regulation in autism with minimally verbal ability or intellectual disability

Conditions: Autism Spectrum Disorder; Minimally Verbal Ability; Intellectual Disability

Summary: the investigator would like to investigate the impact of theta-burst stimulation over left dlpfc in autism with minimally verbal ability or intellectual disability


Eligibility criteria:
inclusion criteria: * diagnosis of autism spectrum disorder, confirmed by dsm-5. * individuals with minimal verbal ability or intellectual disability (fsiq \< 70). exclusion criteria: * current or past severe neurological disorders, such as epilepsy, or significant visual or hearing impairments. * current or past severe systemic diseases, such as cardiovascular disease, diabetes, or multiple sclerosis. * history of severe brain injury. * presence of implanted metal devices, such as a pacemaker or medication pump. * current or past severe psychiatric disorders, such as schizophrenia, bipolar disorder, or major depressive disorder. * pregnancy. * significant brain abnormalities, such as intracranial space-occupying lesions. * family history of epilepsy. * history of febrile seizures. * concurrent use of medications that increase the risk of seizures. * sleep disorders during rtms procedures. * skin lesions or trauma at the stimulation site. * deemed ineligible by the principal investigator (pi). * participation in another clinical trial within the past month. * suicidal ideation or suicide attempts within the past year.
expanded access protocol to provide patisiran to patients with transthyretin-mediated amyloidosis with cardiomyopathy

Conditions: Transthyretin-mediated Amyloidosis With Cardiomyopathy; ATTR Amyloidosis With Cardiomyopathy

Summary: the objective of the study is to assess the long-term safety of patisiran in patients with attr amyloidosis with cardiomyopathy as assessed by a review of adverse events (aes).

choosing to participate in an expanded access program is an important personal decision. talk with your doctor and family members or friends about deciding to join a research study. to learn more about this study, please have your doctor contact the study research staff using the contacts provided.

Eligibility criteria:
inclusion criteria: * documented diagnosis of attr amyloidosis with cardiomyopathy, classified as either hattr amyloidosis with cardiomyopathy or wtattr amyloidosis with cardiomyopathy; and * had an inadequate response to or could not tolerate standard of care, in the opinion of the investigator. * is not eligible for on-label use of commercial patisiran in the opinion of the investigator. exclusion criteria: * new york heart association (nyha) class iv * nyha class iii and attr amyloidosis disease stage 3 (defined as both n-terminal prohormone b-type natriuretic peptide (nt-probnp) \>3000 ng/l and estimated glomerular filtration rate \[egfr\] \<45 ml/min/1.73 m\^2). \[gillmore 2018\] * current or future participation in another investigational device or drug study, scheduled to occur during this study, or has received an investigational agent or device within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to dosing (day 1). patients who have previously participated in a gene therapy trial for hattr amyloidosis. * patients currently enrolled in, eligible for inclusion in, or who have dropped out of an ongoing interventional (therapeutic) clinical trial related to attr amyloidosis.

Keywords: rnai therapeutic amyloidosis cardiomyopathy ttr transthyretin
a method to evaluate glucose-dependent insulin secretion in healthy males (mk-0431-179)

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (mtt) during a hyperglycemic clamp (hcg) procedure.


Eligibility criteria:
inclusion criteria: * subject is an asian indian male between 18 to 45 years of age * subject is in good health * subject is a nonsmoker or has not used nicotine-containing products for six months * subject is willing to avoid strenuous activity exclusion criteria: * subject has a history of stroke, seizures, or major neurological disorders * subject has irritable bowel disease or recurrent nausea, vomiting, diarrhea, or abdominal pain * subject has a history of high blood pressure requiring treatment * subject has history of cancer * subject has a history of diabetes
identify specific peripheral blood mononuclear cell (pbmc) mirna as biomarkers for inflammatory bowel disease (ibd)

Conditions: Inflammatory Bowel Diseases

Summary: to find high sensitivity and specificity biomarkers to better diagnose and monitor progression of inflammatory bowel disease (ibd). in this study, we try to find mirnas that can used to diagnose or monitor progression of ibd by exploring differential expression of mirnas in peripheral blood mononuclear cells (pbmcs) from crohn's disease, ulcerative colitis and healthy controls. and we further validate these mirnas in a larger population to assess their function as biomarkers.

incidence of inflammatory bowel disease (ibd) has been rising in the past decades. however, diagnosis and differential diagnosis of ibd still lack gold standard. to diagnose ibd, physicians need to combine clinical manifestation, lab results, image examination, endoscopy examination and pathology. after diagnosis, patients still need to monitor their disease progression. the most accurate way is to do endoscopy examination, however, endoscopy examination is an invasive, expensive and uncomfortable procedure. at present, c-reactive protein (crp), erythrocyte sedimentation rate (esr) and fecal calprotectin are used as main noninvasive biomarkers to monitor progression routinely. but their specificities are still unsatisfactory. so, it's urgent to find high sensitivity and specificity biomarkers to better diagnose and monitor progression of ibd. in this study, we try to find mirnas that can used to diagnose or monitor progression of ibd by exploring differential expression of mirnas in peripheral blood mononuclear cells (pbmcs) from crohn's disease, ulcerative colitis and healthy controls. and we further validate these mirnas in a larger population to assess their function as biomarkers.

Eligibility criteria:
inclusion criteria: * diagnosed as crohn's disease (cd) or ulcerative colitis (uc) according to world health organization (who) criteria * vital signs are stable exclusion criteria: * refuse to sign consent * refuse to do examination to assess their disease progression * cd patients only upper gastrointestinal tract (gi) is involved (l4) * had colectomy or in artificial opening status * have other autoimmune comorbidity * had severe infection within a week * had surgery within a month * have malignant tumor * pregnancy or lactation
address - adult deformity robotic vs. freehand surgery to correct spinal deformity

Conditions: Scoliosis; Kyphosis; Kyphoscoliosis; Spinal Deformity; Spondylosis

Summary: to quantify potential short- and long-term benefits of robotically-guided minimally invasive (mis) or open-approach spine surgery in adult patients undergoing multi-level spinal instrumentation surgery, in comparison to image- or navigation-guided instrumentation in a matching cohort of control patients, performed using a freehand technique, both in mis and open approaches.


Eligibility criteria:
inclusion criteria: 1. adult patients (age 21 years and older), undergoing long (5 consecutive vertebrae or more) spinal fusion surgery, between t1 to the sacrum. 2. cases may include surgeries involving iliac screws (e.g., galveston technique or s2ai screws) although these screws will not be included in the data analysis. 3. cases may include augmented cases (when one or more of the screws are inserted into vertebrae after a vertebral augmentation procedure, such as kyphoplasty or vertebroplasty). 4. patient capable of complying with study requirements 5. signed informed consent by patient exclusion criteria: 1. infection or malignancy 2. primary abnormalities of bones (e.g. osteogenesis imperfecta) 3. primary muscle diseases, such as muscular dystrophy 4. neurologic diseases (e.g. charcot-marie tooth, guillain-barre syndrome, cerebral palsy, spina bifida, or neurofibroma) 5. spinal cord abnormalities with any neurologic symptoms or signs 6. spinal cord lesions requiring neurosurgical interventions, such as hydromyelia 7. paraplegia 8. patients who have participated in a research study involving an investigational product in the 12 weeks prior to surgery 9. any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study. 10. pregnancy 11. patient cannot follow study protocol, for any reason 12. patient cannot or will not sign informed consent

Keywords: robotic-guided spinal fusions scoliosis kyphoscoliosis spinal deformity spondylosis
infant formula and toddler drink feeding intervention

Conditions: Respiratory Infections in Children

Summary: the purpose of this randomized, multi-center, controlled, double-blind, parallel study is to evaluate the health and developmental outcomes of children fed a new infant formula and toddler drink through 24 months of age.


Eligibility criteria:
inclusion criteria: * participant is judged to be in good health as determined from participant's medical history * participant is a singleton from a full-term birth with a gestational age of 37 - 42 weeks * participant's birth weight was ≥ 2490 g (\~5 lbs. 8 oz.) * if parent(s) elect to formula feed the participant they confirm their intention to feed their participant the study product as the sole source of feeding until 4 months of age, and as the sole milk beverage during the first 12 months of life * if parent(s) elect to formula feed the participant, they confirm their intention to feed the participant the assigned toddler drink from 12 months of life to 24 months of life as the primary milk beverage * if parent(s) elect to feed the participant mother's human milk, they confirm that their infant was exclusively fed mother's human milk since birth and confirm their intention to continue exclusively feeding human milk as the sole source of feeding through 4 months of age * if parent(s) of human milk fed participant elect to supplement or wean after 4 months to 24 months of age, they confirm their intention to use the supplemental/weaning formula or toddler drink as the primary milk beverage * parent(s) of formula-fed participant confirm their intention not to administer vitamin or mineral supplements, from enrollment through the duration of the study * parent(s) confirm their intention not to administer solid foods or juices to the participant from enrollment through 6 months of age * participant's parent(s) has voluntarily signed and dated an informed consent form (icf), approved by an institutional review board/independent ethics committee (irb/iec) and provided health insurance portability and accountability act (hipaa) (or other applicable privacy regulation) authorization prior to any participation in the study. exclusion criteria: * an adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development * participant is taking and plans to continue medications (including over the counter (otc), home remedies, herbal preparations, prebiotics or probiotics, or rehydration fluids that might affect gi tolerance * participant is in another study that has not been approved as a concomitant study * participant has been treated with antibiotics prior to enrollment
laryngectomy education

Conditions: Total Laryngectomy

Summary: patients undergoing total laryngectomy are at high risk for 30-day unplanned readmission. many of these readmissions are related to stomal care, and it is thought that the readmissions could be prevented with better patient and caregiver education. the investigators are studying the effect of a comprehensive perioperative education program on 30-day unplanned readmission for patients undergoing total laryngectomy. the comprehensive perioperative education program will include the following additional interventions: -preoperative visit with the speech pathologist for explanation of laryngectomy physiology, stomal education, and alaryngeal voice rehabilitation. participants will be expected to undergo this intervention and to attend it with their "laryngectomy coach" (a family member or friend to accompany the patient through the education process), but failure to meet with the speech pathologist will not exclude a patient from the study. * preoperative education class with a designated ent laryngectomy nurse for patient and caregiver. the hands-on class introduces the patient and laryngectomy coach to the basics of stomal care. participants and their "laryngectomy coach" will be expected to attend the preoperative education class * printed laryngectomy journey guide given to patients at time of study enrollment for patient/caregiver. this journey guide details the preoperative, in-hospital, and post-discharge course and is provided as a reference throughout their journey. * formalized, nursing administered practical evaluation of minimal competency of laryngectomy care for patient and caregiver/laryngectomy coach. this study will follow patients prospectively from the time of study commencement and then assess changes in patient knowledge before and after the education intervention. it will also compare rate of stomal complications and readmission rates to institutional historical averages to assess improvement in quality care.


Eligibility criteria:
inclusion criteria: * planned total laryngectomy at barnes jewish hospital * age 18 or older * understand spoken or written english language * able to provide informed consent. exclusion criteria: -none
transcranial pulse stimulation. a potential treatment for early dementia

Conditions: Alzheimer Disease

Summary: alzheimer's disease (ad) is characterized by the absence of treatments to slow, stop, or reverse its course, with patients finally losing cognitive functions, skills and independence. it is a chronic degenerative disease with high social and medical burden worldwide: ad ranked third among neurological disorders in terms of disability-adjusted life years (daly) rates. the primary aim of the research protocol is to improve care for patients with ad, by implementing, with an innovative method, the currently available repertoire of neuromodulation techniques. for this aim, we will investigate whether transcranial pulse stimulation (tps) may induce cognitive improvement in patients with an early stage of dementia.

aims of the project: the primary aim of our research protocol is to improve care for patients with ad by investigating whether transcranial pulse stimulation (tps) may induce cognitive improvement in patients with an early stage of dementia. additional aims will include the investigation of the neurophysiological profile of patients and the search for a correlation between neuropsychological and neurophysiological data with the serum levels of brain-derived neurotrophic factor (bdnf) and of vascular endothelial growth factor (vegf). materials and methods: following a rigorous selection, included patients will be treated through a real/sham structured tps protocol and followed-up with respect to cognitive improvement, by comparing baseline and follow-up clinical scores. a double blind sham-controlled study will be performed: patients will be assigned randomly to receive tps or sham tps for 4 weeks in a parallel groups, double-blind study. patients will receive ether tps or sham treatment once a day for five days a week for the whole period and will be assessed according to the following schedule: baseline (t0); at two weeks following the start of tps (t1); at 1 month following the start of tps (t2); at 2 months following the start of tps (t3); at 6 months following the start of tps (t4). electroencephalography (eeg) and somatory evoked potentials (sep) will be contextually recorded in all patients, to compare neurophysiological data of patients treated with real tps and sham stimulation. moreover, a serum sample will be collected from patients at baseline, at the end of the stimulation period and at the 6-month follow-up, to compare preprocedural and postprocedural levels of serum bdnf and vegf.

Eligibility criteria:
inclusion criteria: * age\>18 years * diagnosis of early dementia according to current international guidelines * disease duration of at least 12 months * consent to participate in the study. exclusion criteria: * medical instability interfering with standard neurological assessment * any contraindication to preliminary mri for mr-based real-time neuronavigation * comorbidities which may interfere with cognitive status * any contraindication to transcranial pulse stimulation.

Keywords: alzheimer&amp;#39;s disease transcranial pulse stimulation dementia